Abstract
Diabetic nephropathy is one of the major causes of kidney failure, accounting for ~44% of all cases. In spite of the significant mortality rate of diabetic nephropathy, specific and effective treatment is still eluding. Identification of genetic determinants and understanding their role in the progression of disease are essential for developing diagnostic tools and effective therapy. Drosophila melanogaster is a genetically tractable model organism and is being used for understanding the genetic basis of several human diseases. Drosophila has a well developed renal system and shares conserved developmental and functional processes with humans. Apart from similarities in renal system, type 1 and type 2 diabetes can be induced in Drosophila following mechanisms similar to those in human. This review discusses the current therapies available for diabetic nephropathy and examines the potential of Drosophila renal system as a model for identifying drug targets for diabetic nephropathy and screening of the potential drugs for their efficacy.
Keywords: Diabetic nephropathy, Drosophila melanogaster, podocytes, nephrocytes, Drosophila renal organ, therapeutic agents.
Current Drug Targets
Title:Drosophila Renal Organ as a Model for Identification of Targets and Screening of Potential Therapeutic Agents for Diabetic Nephropathy
Volume: 19 Issue: 16
Author(s): Lavi Rani and Naveen Kumar Gautam*
Affiliation:
- Embryotoxicology Laboratory, Environmental Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIRIITR), Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow- 226001, Uttar Pradesh,India
Keywords: Diabetic nephropathy, Drosophila melanogaster, podocytes, nephrocytes, Drosophila renal organ, therapeutic agents.
Abstract: Diabetic nephropathy is one of the major causes of kidney failure, accounting for ~44% of all cases. In spite of the significant mortality rate of diabetic nephropathy, specific and effective treatment is still eluding. Identification of genetic determinants and understanding their role in the progression of disease are essential for developing diagnostic tools and effective therapy. Drosophila melanogaster is a genetically tractable model organism and is being used for understanding the genetic basis of several human diseases. Drosophila has a well developed renal system and shares conserved developmental and functional processes with humans. Apart from similarities in renal system, type 1 and type 2 diabetes can be induced in Drosophila following mechanisms similar to those in human. This review discusses the current therapies available for diabetic nephropathy and examines the potential of Drosophila renal system as a model for identifying drug targets for diabetic nephropathy and screening of the potential drugs for their efficacy.
Export Options
About this article
Cite this article as:
Rani Lavi and Gautam Kumar Naveen *, Drosophila Renal Organ as a Model for Identification of Targets and Screening of Potential Therapeutic Agents for Diabetic Nephropathy, Current Drug Targets 2018; 19 (16) . https://dx.doi.org/10.2174/1389450119666180808114533
DOI https://dx.doi.org/10.2174/1389450119666180808114533 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Pilot Study of Eyesight Characteristics and Thickness of the Retinal Nerve Fiber and Ganglion Cell-inner Plexiform Layers in Adolescent Patients with Type one Diabetes Mellitus on an Insulin Pump
Current Pharmaceutical Design Anti-Phospholipase A2 Receptor Autoantibody: A New Biomarker for Primary Membranous Nephropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Homeobox Genes and Human Genetic Disorders
Current Molecular Medicine Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy
Current Pharmaceutical Design Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease
Current Drug Metabolism Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Protecting Endothelium in Cardiovascular Diseases
Current Medicinal Chemistry Ghrelin and the Brain-gut Axis as a Pharmacological Target for Appetite Control
Current Pharmaceutical Design Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Endocrinological Aspects of Proteinuria and Podocytopathy in Diabetes: Role of the Aldosterone/Mineralocorticoid Receptor System
Current Diabetes Reviews Antiretroviral Drugs and The Kidney: Dosage Adjustment and Renal Tolerance
Current Pharmaceutical Design Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases
Current Pharmaceutical Design From Polypharmacology to Target Specificity: The Case of PARP Inhibitors
Current Topics in Medicinal Chemistry